ModiQuest modiquest.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

ModiQuest (CRO) focus is on generation of recombinant monoclonal antibodies (animal, human). The company use antigen specific B-cell selection combined with efficient hybridoma generation or direct antibody cDNA cloning from selected B-cells. MQR offers custom phage display services.

ModiQuest (CRO) focus is on generation of recombinant monoclonal antibodies (animal, human). The company use antigen specific B-cell selection combined with efficient hybridoma generation or direct antibody cDNA cloning from selected B-cells. MQR off...Show all

Company (Alive / Active)

Phone:

Fax:

Schoutstraat 58

6525 XV
Netherlands

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
ModiQuest $0M Oct 10, 2019
See all 12 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related ModiQuest Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Iomai Corporation

Gaithersburg, Maryland, United States
AcquiredIomai Corporation is developing vaccines and immune system stimulants delivered through needle-free transcutaneous immunizationLogin to see details

PharmAthene

Annapolis, Maryland, United States
Alive / ActivePharmAthene's primary objective is the development of effective countermeasures to a range of biological and chemical threats having potential lethal effects for the military or civilian populations. The Company is developing Valortim, an anthrax monoclonal antibody, in collaboration with Medarex, Inc. for pre- and post exposure prophylaxis and treatment, as well as Protexia, a recombinant human butyrylcholinesterase for treatment following exposure to chemical nerve agents.Login to see details
See all 12 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Anti-inflammatory agents Jun 04, 2009 Aug 01, 2017 Patent
Plexin d1 as a target for tumor diagnosis and therapy Jul 03, 2012 Aug 23, 2016 Patent
Anti-inflammatory agents Dec 10, 2010 Aug 18, 2015 Patent
Peptidylarginine deiminase (pad) inhibitors Dec 10, 2010 Mar 26, 2013 Patent
Anti-inflammatory agents Jun 22, 2017 Application
See all 8 patents